Friday, July 10, 2026

pharma · Glycogen storage disease type II · Niemann-Pick disease

Sanofi Winthrop Industrie

Sanofi Winthrop Industrie drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

ANTONY, FR HQ
12 Employees
EMA registrant Type
Company details
Status
Public
HQ
ANTONY, FR
Employees
12
Programs
2
Drugs
6
Patents
0
Intelligence · Drug Pipeline

Sanofi Winthrop Industrie pipeline

Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Sanofi Winthrop Industrie drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

6 compounds
  1. avalglucosidase alfa

    Alimentary tract and metabolism (A16)

    Alimentary tract and metabolism (A16) compound in Sanofi Winthrop Industrie's portfolio. Molecular target: Glycogen.

    Target
    Glycogen
    Mechanism
    Glycogen hydrolytic enzyme
  2. US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist
  3. Development asset linked to Sanofi Winthrop Industrie in public FDA and regional records.

  4. olipudase alfa

    Alimentary tract and metabolism (A16)

    Alimentary tract and metabolism (A16) compound in Sanofi Winthrop Industrie's portfolio. Molecular target: Sphingomyelin.

    Target
    Sphingomyelin
    Mechanism
    Sphingomyelin hydrolytic enzyme
  5. Development asset linked to Sanofi Winthrop Industrie in public FDA and regional records.

  6. Development asset linked to Sanofi Winthrop Industrie in public FDA and regional records.